President Donald Trump’s plan to import cheap Canadian drugs overlooks a crucial fact: Canada’s pharmaceutical supply chain is beholden to the drugmakers.
Not putting all of your economic eggs in one basket has always been sound advice, and over the past couple of decades, U.S. businesses have—slowly—started to apply it. In the 1950s, U.S. exports constituted only 5% of gross domestic product. Today they’re 14%—a record high that’s still rising. Yet the rate is still far below a country like Germany, where exports account for roughly 50% of GDP.
The Trump administration said Wednesday it will create a pathway allowing Americans to legally and safely import lower-cost prescription drugs from Canada for the first time, reversing years of opposition from federal health authorities.
The Pharmaceutical Research and Manufacturers of America, which represents leading drugmakers including Eli Lilly and Co., reported spending $6.2 million in the quarter. Meanwhile, Lilly boosted its own spending on lobbying.
In a few days, some of the nation’s most important African American leaders—in business, politics, entertainment and philanthropy—will descend on Indianapolis for the National Urban League Conference.
The drug rebate rule would have ended a widespread practice in which drugmakers give rebates to insurance middlemen in government programs such as Medicare. The idea was to channel that money to consumers instead.
The multibillion-dollar merger would combine Elanco, the fourth-largest global player in animal health, with Bayer’s pet-health division, which ranks fifth in veterinary medicine, Reuters reported. The combination would create a dominant force in the industry.
Responding to a lawsuit by Eli Lilly and two other companies, a federal judge Monday blocked a major White House initiative on prescription drug costs, saying the Trump administration lacked the legal authority to require drugmakers to disclose their prices in TV ads.
Ryan Kitchell oversees a wide variety of business operations at the state’s largest health system. His departure comes as IU Health is in the midst of numerous capital projects.
Carroll uses Twitter, a New York Times column, blog post, podcast, videos and books to publish his findings on just about any health issue he thinks needs explaining or correcting.
Patricia Martin, 58, former chief operating officer of Lilly’s diabetes division, will start her new job July 1, leading an organization that promotes and invests in the state’s life sciences sector.
Several diabetes and health care advocacy groups on Thursday announced a seven-figure fundraising campaign to help fund their fight against what they consider “skyrocketing” insulin prices.
Local tech advocacy group TechPoint is partnering with TMap, an Indianapolis startup headed by former Angie’s List CEO Bill Oesterle, and five blue-chip companies to bring far flung native Hoosiers back to the state to work.
Array’s stock was already at a record before the deal announcement, following the company’s news last month of positive clinical trial results using Braftovi and Mektovi with Indianapolis-based Eli Lilly and Co.’s Erbitux.
